• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BSX aims for double-digit earnings growth | Medtech Wall Street news for the week of May 4, 2015

BSX aims for double-digit earnings growth | Medtech Wall Street news for the week of May 4, 2015

May 7, 2015 By MassDevice Contributors Network

Boston Scientific aims for double-digit earnings growth

May 1, 2015 by Brad Perriello

Boston Scientific aims for double-digit earnings growth

Boston Scientific CEO Mike Mahoney, who’s overseen a turnaround at the medical device giant since taking over the corner office in 2012, today said the company is targeting double-digit earnings growth each year for the next 6 years.

Mahoney, speaking at the Marlborough, Mass.-based company’s investor day presentation in New York this morning, said Boston expects to post adjusted earnings per share of 88¢ to 92¢ this year, excluding foreign exchange effects. Read more

Profound Medical goes public in reverse merger

May 1, 2015 by Mark Hollmer

Profound Medical goes public in reverse merger

Profound Medical said it’s slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.

The proceeds will help support Profound Medical’s 110-patient pivotal trial of the Tulsa-Pro MRI-guided ultrasound ablation device to treat prostate cancer. Read more

Pavmed files for $23m IPO

May 4, 2015 by Brad Perriello

Pavmed files for $23m IPO

The entrepreneurs behind a quartet of medical device companies is betting their formula can cut down on the time and cost of getting medtech to market with a $23 million initial public offering.

Pavmed is developing devices in 5 areas, according to its IPO registration: The PortIO long-term implantable vascular access device; the Caldus line disposable tissue ablation devices, including renal denervation for hypertension; the CarpX percutaneous device to treat carpal tunnel syndrome; the NextCath self-anchoring short-term catheter; and the NextFlo disposable infusion pump. Read more

Boston Scientific's Mahoney is bullish on Watchman

April 29, 2015 by MassDevice

Boston Scientific's Mahoney is bullish on Watchman

Boston Scientific expects more hospitals will be able to offer its new atrial fibrillation treatment starting by the end of the 3rd quarter as it paces the product’s rollout to give physicians time to learn how to use it, CEO Mike Mahoney said yesterday.

The device, called Watchman, was approved by U.S. regulators last month as an alternative to long-term use of blood thinners such as warfarin for patients at high risk of stroke. Read more

Euronext suspends Carmat shares after artificial heart patient dies

May 5, 2015 by MassDevice

Euronext suspends Carmat shares after artificial heart patient dies

Trading in Carmat shares was suspended after the company’s 2nd artificial heart patient died May 2, 9 months after receiving the transplant.

A source close to the matter said the Euronext stock exchange granted the suspension to give medical teams time to pinpoint the reasons for the death, and that a statement could be issued after the market’s close. Read more

Filed Under: News Well, Wall Street Beat Tagged With: Boston Scientific, Carmat Inc., Cruzar Medsystems, Euronext, Kaleidoscope Medical, Pavilion Medical Innovations, Pavmed, Profound Medical Inc., Saphena Medical, Vortex Medical

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy